Hamuryudan Vedat, Hatemi Gulen, Tascilar Koray, Yurdakul Sebahattin, Mat Cem, Ozyazgan Yilmaz, Seyahi Emire, Ugurlu Serdal, Yazici Hasan
From the Behçet's Syndrome Research Center, Istanbul University, Istanbul, Turkey.
J Rheumatol. 2014 Apr;41(4):735-8. doi: 10.3899/jrheum.130847. Epub 2014 Feb 15.
To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term.
Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6±1.1 years ago were evaluated for immunosuppressive use during the posttrial period.
We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not.
Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.
检验关于在疾病早期使用秋水仙碱可长期减少白塞病（BS）患者免疫抑制剂使用量这一假设。
对16.6±1.1年前参与秋水仙碱双盲、安慰剂对照试验的白塞病患者在试验后阶段的免疫抑制剂使用情况进行评估。
我们能够联系到90/116名患者；28名（31%）在试验后阶段接受了免疫抑制剂治疗，其中14名来自秋水仙碱治疗组。接受免疫抑制剂治疗的患者与未接受免疫抑制剂治疗的患者在试验后秋水仙碱的使用情况及累积使用时长方面相似。
即使在疾病早期开始持续使用秋水仙碱，从长期来看似乎也不会减少免疫抑制剂的使用。
